Compare StocksADBE vs MRNA

Adobe Inc. (ADBE) vs Moderna, Inc. (MRNA): Which Is the Better Buy in 2026?

As of 2026-06-19, ADBE is undervalued at $195, with a DCF intrinsic value of $558 and a margin of safety of 65%. MRNA is overvalued at $64, with an intrinsic value of $6 and a margin of safety of -963%. Of the two, ADBE has the wider margin of safety.

ADBE
Adobe Inc.
$195.16
VS
MRNA
Moderna, Inc.
$63.96

Rewards

ADBE
  • Adobe Inc. has maintained ROIC above 15% for 4 consecutive years, indicating a durable competitive advantage.
  • Gross margin of 89.4% indicates strong pricing power — typical of businesses with significant intellectual property or brand strength.
  • Adobe Inc. scores 100/100 on the Economic Moat Score (Wide Moat), with roic consistency as the strongest competitive dimension.
MRNA

    Risks

    ADBE
      MRNA
      • ROIC has declined by 67.4 percentage points over the past 4 years, which may signal competitive erosion.
      • Gross margin of -69.9% is low, suggesting a competitive or commodity-like market with limited pricing power.
      • Moderna, Inc. scores only 17/100 on the Economic Moat Score, suggesting limited durable competitive advantages.

      Key Valuation Metrics

      Learn more →
      ADBE
      MRNA
      Valuation
      $9.22B
      Free Cash Flow
      $-20.00M
      11.88%
      FCF Yield
      -0.08%
      11.16
      Trailing P/E
      N/A
      7.09
      Forward P/E
      -15.21
      Quality & Moat
      37.82%
      ROIC
      -26.47%
      62.95%
      ROE
      -36.56%
      89.40%
      Gross Margin
      -69.89%
      0.57
      PEG Ratio
      N/A
      Balance Sheet Safety
      0.13
      Net Debt / Equity
      Net cash
      N/A
      Interest Coverage
      N/A
      0.15
      Net Debt / EBITDA
      N/A
      0.00%
      Dividend Yield
      0.00%
      ADBE: 5Ties: 1MRNA: 3
      ADBEMRNA

      Historical Fundamentals

      Learn more →
      ADBE

      Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

      MRNA

      Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

      Price ÷ Earnings Per Share — how many years of current earnings you're paying for at today's price. Lower P/E may indicate undervaluation. The dashed forward point is the forward P/E — today's price ÷ analyst consensus EPS.

      $1 Retained Earnings Test

      Learn more →
      ADBE
      $-0.60
      created per $1 retained over 3 years
      Market Cap Declined
      Σ Retained
      $18.12B
      Δ Market Cap
      $-10.93B
      Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
      > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer
      MRNA
      N/A
      Net losses over 3 years — test not applicable
      Company had negative cumulative retained earnings
      Σ Retained
      $-11.10B
      Δ Market Cap
      $-57.53B
      Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
      > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

      Buffett's "$1 Test": For every $1 of earnings retained, has management created at least $1 of market value?
      > $1 created per $1 retained = Value Creator · < $1 created = Value Destroyer

      Discounted Cash Flow (DCF) Analysis

      Learn more →
      ADBE
      65.0% Margin of Safety
      Price is 65.0% below estimated fair value
      Current Price: $195.16
      Fair Value: $558.28
      Strongly undervalued
      Undervalued
      Fairly valued
      Overvalued
      Strongly overvalued
      MRNA
      962.8% Overvalued
      Price is 962.8% above estimated fair value
      Current Price: $63.96
      Fair Value: $6.02
      Strongly undervalued
      Undervalued
      Fairly valued
      Overvalued
      Strongly overvalued

      Reverse DCF — Market-Implied Growth

      Learn more →
      ADBE

      What growth rate is the market pricing in at $195?

      -1.6%
      Market-Implied Owner Earnings Growth
      Standard FCF implies -4.0%

      The market implies -1.6% Owner Earnings growth, below historical trends — potential opportunity.

      Standard FCF implies a more demanding -4.0%, reflecting heavy growth investment expected to generate future returns.

      MRNA

      Requires positive FCF to compute implied growth rate.

      Economic Moat Score

      Learn more →
      ADBE
      100/100
      Wide Moat
      70+ Wide · 40-69 Narrow · <40 None

      Wide moat with strength across all dimensions. ROIC Consistency is the standout factor.

      Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 4 years of fundamental data.
      MRNA
      17/100
      No Moat
      70+ Wide · 40-69 Narrow · <40 None

      No durable competitive advantage detected. The business shows limited evidence of pricing power, consistent returns, or capital efficiency.

      Composite score measuring competitive advantage durability across four dimensions: returns above cost of capital, pricing power stability, revenue predictability, and capital efficiency. Based on 5 years of fundamental data.

      Forensic Accounting

      Learn more →
      ADBE
      -2.85
      Unlikely Manipulator
      Above -1.78 = likely manipulator · -2.22 to -1.78 = grey zone

      M-Score Trend

      Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.
      MRNA

      Insufficient data for Beneish M-Score calculation (requires 2+ years).

      Beneish's 8-variable model estimates the probability of earnings manipulation. An M-Score above -1.78 signals elevated risk — companies in this range have historically been 3-5× more likely to be manipulating earnings. Scores between -2.22 and -1.78 fall in a grey zone warranting further investigation.

      Ownership Breakdown

      Learn more →
      ADBE
      Insiders 0.2%Institutions 88.1%Retail & Other 11.7%
      No. of Institutional Holders3,191
      High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.
      MRNA
      Insiders 7.3%Institutions 78.9%Retail & Other 13.7%
      No. of Institutional Holders1,044
      High insider ownership aligns management incentives with shareholders — a key signal in Buffett-style analysis. Institutional concentration can indicate smart-money conviction but also crowding risk.

      High insider ownership aligns management incentives with shareholders. Institutional concentration can indicate smart-money conviction but also crowding risk.

      Insider Buying Activity

      Learn more →
      ADBE
      0
      Buys (3M)
      0
      Buys (12M)
      DURN DANIEL J
      Chief Financial Officer
      $507,758
      @ $390.58 · 2025-03-20
      RICKS DAVID A
      Director
      $998,946
      @ $443.98 · 2025-01-28
      Open market purchases · includes direct & indirect ownership · excludes option exercises
      MRNA
      0
      Buys (3M)
      0
      Buys (12M)
      SAGAN PAUL L
      Director
      $1.00M
      @ $31.76 · 2025-03-03
      BANCEL STEPHANE J
      Chief Executive Officer
      $5.00M
      @ $31.22 · 2025-03-03
      Open market purchases · includes direct & indirect ownership · excludes option exercises

      Open market purchases · includes direct & indirect ownership · excludes option exercises.

      Insider Selling Activity

      Learn more →
      ADBE
      2
      Sells (3M)
      4
      Sells (12M)
      Total value (12M): $1.05M
      FORUSZ JILLIAN
      Officer
      $185,915
      @ $246.25 · 2026-04-30
      DURN DANIEL J
      Chief Financial Officer
      $331,355
      @ $248.02 · 2026-04-20
      DURN DANIEL J
      Chief Financial Officer
      $485,323
      @ $294.85 · 2026-01-27
      FORUSZ JILLIAN
      Officer
      $50,344
      @ $337.88 · 2025-10-31
      FORUSZ JILLIAN
      Officer
      $175,828
      @ $380.58 · 2025-05-02
      FORUSZ JILLIAN
      Officer
      $145,567
      @ $435.83 · 2025-01-28
      BELSKY SCOTT K
      Officer
      $2.05M
      @ $431.61 · 2025-01-27
      BANSE AMY L
      Director
      $333,300
      @ $550.00 · 2024-12-06
      FORUSZ JILLIAN
      Officer
      $327,987
      @ $485.19 · 2024-10-29
      BELSKY SCOTT K
      Officer
      $232,525
      @ $483.42 · 2024-10-25
      BELSKY SCOTT K
      Officer
      $1.14M
      @ $511.48 · 2024-10-16
      DURN DANIEL J
      Chief Financial Officer
      $3.35M
      @ $515.44 · 2024-09-17
      GARFIELD MARK S.
      Officer
      $52,089
      @ $537.00 · 2024-07-25
      BELSKY SCOTT K
      Officer
      $258,297
      @ $537.00 · 2024-07-25
      GARFIELD MARK S.
      Officer
      $85,255
      @ $564.60 · 2024-07-16
      BELSKY SCOTT K
      Officer
      $1.25M
      @ $561.60 · 2024-07-16
      Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives
      MRNA
      3
      Sells (3M)
      6
      Sells (12M)
      Total value (12M): $11.57M
      KLINGER SHANNON THYME
      Officer
      $173,550
      @ $50.00 · 2026-06-04
      HOGE STEPHEN
      President
      $2.58M
      @ $48.40 · 2026-05-15
      HUSSAIN SHAH ABBAS
      Director
      $264,952
      @ $46.63 · 2026-05-01
      KLINGER SHANNON THYME
      Officer
      $726,047
      @ $52.29 · 2026-03-02
      HOGE STEPHEN
      President
      $7.81M
      @ $48.84 · 2026-02-23
      HUSSAIN SHAH ABBAS
      Director
      $13,910
      @ $27.60 · 2025-12-09
      HUSSAIN SHAH ABBAS
      Director
      $8,736
      @ $28.00 · 2025-06-11
      KLINGER SHANNON THYME
      Officer
      $23,637
      @ $44.68 · 2024-12-09
      KLINGER SHANNON THYME
      Officer
      $4,849
      @ $43.29 · 2024-12-03
      HOGE STEPHEN
      President
      $13,595
      @ $43.30 · 2024-12-03
      KLINGER SHANNON THYME
      Officer
      $60,675
      @ $42.79 · 2024-11-29
      HOGE STEPHEN
      President
      $12,452
      @ $42.79 · 2024-11-29
      MOCK JAMES M
      Chief Financial Officer
      $60,761
      @ $42.79 · 2024-11-29
      HOGE STEPHEN
      President
      $12,771
      @ $46.10 · 2024-11-11
      MOCK JAMES M
      Chief Financial Officer
      $42,986
      @ $60.12 · 2024-10-07
      KLINGER SHANNON THYME
      Officer
      $40,539
      @ $73.57 · 2024-09-09
      KLINGER SHANNON THYME
      Officer
      $8,777
      @ $76.99 · 2024-09-03
      HOGE STEPHEN
      President
      $24,483
      @ $76.99 · 2024-09-03
      KLINGER SHANNON THYME
      Officer
      $12,640
      @ $78.02 · 2024-08-29
      HOGE STEPHEN
      President
      $23,408
      @ $78.03 · 2024-08-29
      MOCK JAMES M
      Chief Financial Officer
      $12,640
      @ $78.02 · 2024-08-29
      KLINGER SHANNON THYME
      Officer
      $104,722
      @ $79.39 · 2024-08-28
      MOCK JAMES M
      Chief Financial Officer
      $104,881
      @ $79.40 · 2024-08-28
      HOGE STEPHEN
      President
      $21,363
      @ $84.11 · 2024-08-12
      AFEYAN NOUBAR BOGHOS
      Director
      $1.80M
      @ $119.96 · 2024-07-31
      AFEYAN NOUBAR BOGHOS
      Director
      $1.77M
      @ $117.80 · 2024-07-24
      AFEYAN NOUBAR BOGHOS
      Director
      $1.84M
      @ $122.84 · 2024-07-17
      HOGE STEPHEN
      President
      $1.82M
      @ $121.12 · 2024-07-15
      AFEYAN NOUBAR BOGHOS
      Director
      $1.76M
      @ $117.08 · 2024-07-10
      MOCK JAMES M
      Chief Financial Officer
      $81,465
      @ $118.24 · 2024-07-08
      AFEYAN NOUBAR BOGHOS
      Director
      $1.91M
      @ $127.22 · 2024-06-26
      AFEYAN NOUBAR BOGHOS
      Director
      $2.00M
      @ $133.57 · 2024-06-18
      Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives

      Direct ownership only · excludes indirect, option exercises, planned (10b5-1) sales & derivatives.

      🎭 Mr. Market's Mood

      Learn more →
      ADBE
      FearGreed
      🥶Extreme Fear(17/100)

      "Mr. Market is panicking — potential buying opportunity if fundamentals are strong"

      Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.
      MRNA
      FearGreed
      😏Greed(61/100)

      "Market is optimistic — be cautious and ensure you have a margin of safety"

      Composite sentiment score based on 6 market signals. Inspired by Buffett's "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

      Composite sentiment score based on market signals. Inspired by Buffett’s "Mr. Market" allegory — fear = potential opportunity, greed = potential risk. Must be used alongside fundamental analysis, not in isolation.

      ⚖️ Buffett Signal

      Learn more →
      ADBE
      Awaiting DCF Data

      The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

      DCF Margin of Safety: N/AMr. Market's Mood: Extreme Fear (17)
      MRNA
      Awaiting DCF Data

      The Buffett Signal cross-references market sentiment with DCF valuation. Configure the DCF Analysis above to generate a signal.

      DCF Margin of Safety: N/AMr. Market's Mood: Greed (61)
      View ADBE Full AnalysisView MRNA Full Analysis

      Frequently Asked Questions: ADBE vs MRNA

      Is Adobe Inc. or Moderna, Inc. more undervalued in 2026?

      Based on our discounted cash flow model, ADBE trades at a 65.0% margin of safety (intrinsic value $558 vs. price $195), compared to MRNA's -962.8% margin of safety (intrinsic $6 vs. $64).

      Which stock has a wider economic moat, Adobe Inc. or Moderna, Inc.?

      ADBE scores 100/100 (Wide moat), while MRNA scores 17/100 (None moat). The moat score measures competitive advantage durability across ROIC consistency, margin stability, revenue predictability, and reinvestment efficiency.

      Is Moderna, Inc. in financial distress?

      MRNA's Altman Z-Score of 2.5 places it in the Grey zone, signaling elevated bankruptcy risk. ADBE scores 8.8 (Safe zone). The Altman Z-Score is a five-factor model that predicts insolvency within two years; scores below 1.81 indicate significant distress.

      Which company has better free cash flow, Adobe Inc. or Moderna, Inc.?

      Adobe Inc. (ADBE) generates a 11.9% free cash flow yield, compared to Moderna, Inc.'s -0.1%. A higher FCF yield means the business converts more of its market value into cash that can be returned to shareholders or reinvested.

      Which stock has higher return on invested capital, Adobe Inc. or Moderna, Inc.?

      ADBE earns 37.8% ROIC versus MRNA's -26.5%. A higher ROIC means the company generates more profit per dollar of capital employed, a hallmark of durable competitive advantage in Buffett-style analysis.